<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Gastroenterol Hepatol Bed Bench</journal-id><journal-id journal-id-type="iso-abbrev">Gastroenterol Hepatol Bed Bench</journal-id><journal-id journal-id-type="publisher-id">GHFBB</journal-id><journal-title-group><journal-title>Gastroenterology and Hepatology From Bed to Bench</journal-title></journal-title-group><issn pub-type="ppub">2008-2258</issn><issn pub-type="epub">2008-4234</issn><publisher><publisher-name>Shaheed Beheshti University of Medical Sciences</publisher-name><publisher-loc>Tehran, Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25584176</article-id><article-id pub-id-type="pmc">4285932</article-id><article-id pub-id-type="publisher-id">GHFBB-8-49</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effect of vitamin D3 supplementation on TNF-&#x003b1; serum level and disease activity index in Iranian IBD patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dadaei</surname><given-names>Tahereh</given-names></name></contrib><contrib contrib-type="author"><name><surname>Safapoor</surname><given-names>Mohammad Hosein</given-names></name></contrib><contrib contrib-type="author"><name><surname>Asadzadeh Aghdaei</surname><given-names>Hamid</given-names></name></contrib><contrib contrib-type="author"><name><surname>Balaii</surname><given-names>Hedie</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pourhoseingholi</surname><given-names>Mohammad Amin</given-names></name></contrib><contrib contrib-type="author"><name><surname>Naderi</surname><given-names>Nosratollah</given-names></name></contrib><contrib contrib-type="author"><name><surname>Zojaji</surname><given-names>Homayoon</given-names></name></contrib><contrib contrib-type="author"><name><surname>Azimzadeh</surname><given-names>Pedram</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mohammadi</surname><given-names>Parvaneh</given-names></name></contrib><contrib contrib-type="author"><name><surname>Zali</surname><given-names>Mohammad Reza</given-names></name></contrib></contrib-group><aff id="aff1"><italic>Gastroenterology and Liver Disease Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran</italic></aff><author-notes><corresp id="cor">Reprint or Correspondence: Mohammad Hosein Safapoor, MD. Gastroenterology and Liver Disease Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran. E-mail: safapoor@gmail.com</corresp></author-notes><pub-date pub-type="ppub"><season>Winter</season><year>2015</year></pub-date><volume>8</volume><issue>1</issue><fpage>49</fpage><lpage>55</lpage><permissions><copyright-statement>&#x000a9; 2015 RIGLD, Research Institute for Gastroenterology and Liver Diseases</copyright-statement><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>
<bold>Aim</bold>: The aim of the study was to assess the effectiveness of vitamin D<sub>3 </sub>[1, 25(OH)<sub>2</sub>D<sub>3</sub>] treatment in IBD with regard to tumor necrosis factor-alpha (TNF-&#x003b1;) serum level and clinical disease activity index (CDAI).</p><p>
<bold>Background</bold>: Vitamin D has immune-regulatory functions in experimental inflammatory bowel disease (IBD) and vitamin D deficiency is common in IBD patients.</p><p>
<bold>Patients and methods</bold>: This was a randomized clinical trial on 108 IBD patients with serum 25-OHD levels less than 30ng/ml, which divided into vitamin D and control groups. Vitamin D group received 50000 IU vitamin D<sub>3</sub> for 12 weeks. Before and after the study, TNF-&#x003b1; and 25-OHD serum levels were measured by ELISA method. Data were analyzed using paired t-test, chi-square test and Spearman correlation coefficient. P-values &#x0200b;&#x0200b;less than 0.05 were considered statistically significant.</p><p>
<bold>Results</bold>: Before the intervention no significant difference was found between baseline characteristics and TNF-&#x003b1; serum level of two groups. After intervention TNF-&#x003b1; serum level reduced but this reduction was not statistically significant (p= 0.07, 95% CI: -0.45 to 8.14). The mean serum 25-OHD level of vitamin D increased from 15.54 to 67.89, which was statistically significant (p= 0.00, 95% CI: -61.40 to -43.30). TNF-&#x003b1; level was also associated significantly with CDAI before (Spearman&#x02019;s rho: 0.3, p&#x0003c;0.0001) and after (Spearman&#x02019;s rho: 0.27, P=0.01) intervention. </p><p>
<bold>Conclusion</bold>: Oral supplementation vitamin D<sub>3</sub> significantly increased serum vitamin D levels and insignificantly reduced serum TNF-&#x003b1; level. More studies with larger samples would be beneficial to assess vitamin D<sub>3</sub> supplementation efficient effect in IBD.</p></abstract><kwd-group><title>Key Words</title><kwd>Inflammatory bowel disease</kwd><kwd>TNF-&#x003b1;</kwd><kwd>Vitamin D</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The inflammatory bowel diseases (IBDs), Crohn's&#x000a0;disease&#x000a0;and ulcerative colitis, are chronic&#x000a0;inflammatory&#x000a0;disorders of the gastrointestinal tract.&#x000a0;These diseases characterized by aberrant mucosal immune responses to intraluminal antigens in genetically predisposed individuals (<xref rid="B1" ref-type="bibr">1</xref>). TNF-&#x003b1; and several other pro-inflammatory cytokines, play a main role in the induction and perpetuation of intestinal inflammation in IBDs so that it was shown that treatments against these cytokines particularly anti-TNF-&#x003b1; antibody are effective in IBD patients (<xref rid="B2" ref-type="bibr">2</xref>).</p><p>In addition of genetics and immune factors, environmental factors affect the development of IBD. Twin studies have shown not all people who are genetically predisposed to develop IBD, actually develop IBD and epidemiologic studies have examined numerous environmental factors that alter the expression of the genes and can control IBD development in genetically susceptible subjects (<xref rid="B3" ref-type="bibr">3</xref>-<xref rid="B5" ref-type="bibr">5</xref>).</p><p>Epidemiological studies in IBD demonstrate a more prevalence in northern climates such as Northern Europe and North America (<xref rid="B6" ref-type="bibr">6</xref>). Multiple sclerosis (MS) and type-1 diabetes, two major autoimmune diseases, are similarly most prevalent in countries far from equator, in Scotland and Finland, respectively. Vitamin D available from sunlight exposure is significantly less in these climates, which has been suggested to be a contributing factor to IBD (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). 1,25-Dihydroxyvitamin D<sub>3 </sub>[1,25(OH)<sub>2</sub>D<sub>3</sub>], the bioactive form of vitamin D, has well-known effects on calcium metabolism, bone formation and mineralization. In 1983, the vitamin D receptor (VDR) was discovered in human leukocytes and after that, its identification in skin, placenta, pancreas, breast and other tissues that are not involved in maintaining mineral homeostasis and bone health, has provided new insights into the function of this vitamin as an important immune system regulator (<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref>). In addition, genome-wide screening techniques suggest that VDR polymorphisms are associated with increased susceptibility to both Crohn's disease and ulcerative colitis in human subjects (<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>).</p><p>Vitamin D and VDR deficiency have been shown to exacerbate experimental IBD and treatment of mice with 1,25(OH)<sub>2</sub>D<sub>3 </sub>inhibits the development of disease (<xref rid="B14" ref-type="bibr">14</xref>). Vitamin D and VDR are needed for normal function of two type of regulatory T cells include iNKT cells and CD4/CD8&#x003b1;&#x003b1; intraepithelial lymphocytes. The experimental evidence show that in the absence of vitamin D and VDR, IBD occurs by changes in vitamin D status and VDR signaling and increase the amount of some proinflammatory cytokine production including tumor necrosis factor-&#x003b1; (TNF-&#x003b1;) and interferon-&#x003b3; (<xref rid="B15" ref-type="bibr">15</xref>). Furthermore, animal models suggest that vitamin D is positively involved in maintaining or restoring immune homeostasis, which might be useful in the treatment of IBD. However, it should be noticed that human effects might differ from animal effects due to the interaction between different vitamin D sensitive cells (<xref rid="B16" ref-type="bibr">16</xref>). Vitamin D supplementation trials will further elucidate the immune regulating effects of vitamin D on the immune system of humans.</p><p>The aim of this study was to assess the effectiveness of vitamin D treatment in IBD with regard to reduction of TNF-&#x003b1; level and disease activity index. </p></sec><sec sec-type="methods"><title>Patients and Methods</title><p>
<bold>Study design and participants</bold>
</p><p>The study was a randomized controlled trial, carried out at Taleghani Hospital, Tehran. The study was approved by Research Center for Gastroenterology and Liver Disease Ethics Committee and was registered in the Iranian Registry of Clinical Trial (www.irct.ir) with registration number ID: IRCT2013122915686N1.</p><p>Patients with confirmed inflammatory bowel disease by a gastroenterologist according to established clinical guidelines and criteria based on endoscopic, radiological and histopathological examination were recruited into the study. Exclusion criteria included patients with a, serum 25OHD level more than 30ng/ml, confirmed celiac disease, kidney disorders requiring dialysis or polycystic kidney disease also pregnant patients. Written informed consent was obtained from all patients. </p><p>
<bold>Procedures</bold>
</p><p>The patients were randomly divided into treatment and control group with random block design method. The information was obtained using a questionnaire consisting of demographics, occupation, medical history, smoking, past and current medication. Medication use was classified as ever having used of 5-aminosalicylic acid compounds, immune modulators (ie, azathioprine, 6-mercaptopurine, and methotrexate) and anti-tumor necrosis factor (TNF) biologic agents (ie, infliximab, adalimumab). Disease activity was measured using the ulcerative colitis disease activity index (UCDI) in UC patients and the Crohn's&#x000a0;disease&#x000a0;activity index (CDAI) in CD patients (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>). Moreover, the patients in treatment group received oral vitamin D (cholecalciferol; 50000 units/week) for 12 weeks, while the control group received no experimental treatment. Serum samples were stored at -70&#x002da;C until each participant completed the study. Serum 25-hydroxy vitamin D levels were measured using an enzyme immunoassay (25-hydroxy vitamin DEIA kit; Immunodiagnostics Systems, Boldon, UK) with a measurement sensitivity of 5 nmol/l, and an intra- and inter-assay coefficient of variation of 5.9% and 5.1%, respectively. Also, serum TNF &#x02013;&#x003b1; level was measured with ELISA method by Human TNF alpha ELISA Ready-SET-Go kit produced by eBioscience company (The United States).</p><p>
<bold>Statistical analysis</bold>
</p><p>Continuous variables were expressed using means and standard deviations. The chi-square test and the t-test were used to perform between-groups comparison for categorical and continuous variables, respectively. Moreover, for comparisons within groups, before and after the treatment, paired t-test was performed. The association between quantitative variables was estimated by the Spearman coefficient of correlations. P-values of less than 0.05 were assumed to be significant (p&#x0003c;0.05). </p></sec><sec sec-type="results"><title>Results</title><p>Of 170 potential participants for inclusion criteria, 108 were eligible and were randomized to vitamin D or control groups. 82 participants (76%) completed the study treatment and follow-up, 19 (17.5%) in control group and 7 (6.5%) in vitamin D group withdrew from the study. 108 participants were included in the intention-to-treat analysis. The flow of participants through each stage of the study is shown in figure 1. </p><p>Both groups were similar in age, sex and other baseline characteristics before intervention (table 1). The mean age was 37.36&#x000b1;14.69 years and 38.75&#x000b1;15.73 years in the vitamin D and control groups, respectively and the mean duration of disease was 60.07&#x000b1;58.41 months and 65.74&#x000b1;58.26 months in the vitamin D and control groups, respectively. </p><p>Baseline TNF-&#x003b1; levels did not differ between the vitamin D group and control group [mean TNF-&#x003b1; 33.3 pg/ml (S.D. 29.3 pg/ml) vs. 28.0 pg/ml (S.D. 20.1) p=0.27]. After intervention serum TNF-&#x003b1; levels decreased from mean 33.3 (S.D. 29.3 pg/ml) to mean 26.64 (S.D. 17.56 pg/ml) but this difference was not statistically significant (p=0.07, 95% CI: -0.45 to 8.14).</p><p>At the beginning the mean 25OHD levels in control group was more than vitamin D group significantly, while at the end this mean in vitamin D group was significantly more than control group (p=&#x0003c;0.0001, 95% CI: -61.40 to -43.30). Therefore, in vitamin D group the mean 25OHD levels from 15.54 (S.D. 7.7) increased to 67.89 (S.D. 33.7) but on other side it increased from 21.70 (S.D. 7.8) to 23.90 (S.D. 8.3) in control group.</p><p>TNF-&#x003b1; level was also associated significantly with CDAI (clinical disease activity index) before (Spearman&#x02019;s rho: 0.3, p&#x0003c;0.0001) and after intervention. (Spearman&#x02019;s rho: 0.27, p=0.01).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Noticeable epidemiologic data have shown a correlation of autoimmune disease with sun exposure and decreased vitamin D status. Living at higher latitudes increases the risk of type-1 diabetes, multiple sclerosis, cancers and IBD (19). Immigration from high-risk areas before puberty reduces the risk of multiple sclerosis by approximately 50% (<xref rid="B20" ref-type="bibr">20</xref>). However, vitamin D deficiency is common in patients with IBD even when the disease is in remission (<xref rid="B21" ref-type="bibr">21</xref>). In our study, vitamin D deficiency or insufficiency was found in 119 out of 170 (70%) IBD patients. Some evidence supports the vitamin D supplementation in the treatment of some immune-related disease such as IBD, is increasing. The origin for vitamin D use as an adjuvant therapy in IBD is based on experimental animals and in vitro studies. These studies express that vitamin D has potent immune-regulatory functions and is assumed to be critical to maintain a balanced immune response. As a result, it reduces the pro-inflammatory condition observed in IBD (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). </p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Participant Flow Chart</p></caption><graphic xlink:href="GHFBB-8-49-g001"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline characteristics of vitamin D and control group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Vitamin D</th><th align="center" rowspan="1" colspan="1">Control</th><th align="center" rowspan="1" colspan="1">P-Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"> Disease type, n(%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Ulcerative colitis</td><td align="center" rowspan="1" colspan="1">43(81.1)</td><td align="center" rowspan="1" colspan="1">49(89.1)</td><td align="center" rowspan="2" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Crohn's disease</td><td align="center" rowspan="1" colspan="1">10(18.9)</td><td align="center" rowspan="1" colspan="1">6(10.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years), mean(S.D)</td><td align="center" rowspan="1" colspan="1">37.3 (14.7)</td><td align="center" rowspan="1" colspan="1">38.7 (15.73)</td><td align="center" rowspan="1" colspan="1">0.63</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex, n(%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Female</td><td align="center" rowspan="1" colspan="1">27(50.9)</td><td align="center" rowspan="1" colspan="1">32(58.2)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Man</td><td align="center" rowspan="1" colspan="1">26(49.1)</td><td align="center" rowspan="1" colspan="1">23(41.8)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Disease duration(month), mean(S.D)</td><td align="center" rowspan="1" colspan="1">60.1(58.4)</td><td align="center" rowspan="1" colspan="1">65.7 (58.3)</td><td align="center" rowspan="1" colspan="1">0.61</td></tr><tr><td align="left" rowspan="1" colspan="1">Illeal Disease, n(%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" rowspan="1" colspan="1"> &#x000a0;&#x000a0;&#x000a0;Yes</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="2" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> &#x000a0;&#x000a0;&#x000a0;No</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">55</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking Status, n(%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Current</td><td align="center" rowspan="1" colspan="1">46(86.8)</td><td align="center" rowspan="1" colspan="1">42(76.4)</td><td align="center" rowspan="3" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Ex-Smoker</td><td align="center" rowspan="1" colspan="1">3(5.7)</td><td align="center" rowspan="1" colspan="1">6(10.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Never</td><td align="center" rowspan="1" colspan="1">4(7.5)</td><td align="center" rowspan="1" colspan="1">7(12.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Azathioprine users, n(%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="center" rowspan="1" colspan="1">22(41.5)</td><td align="center" rowspan="1" colspan="1">23(41.8)</td><td align="center" rowspan="2" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;No</td><td align="center" rowspan="1" colspan="1">31(58.5)</td><td align="center" rowspan="1" colspan="1">32(58.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline TNF-&#x003b1; level, mean(S.D)</td><td align="center" rowspan="1" colspan="1">33.3 (29.3)</td><td align="center" rowspan="1" colspan="1">28.0 (20.1)</td><td align="center" rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline25OHD, mean (S.D)</td><td align="center" rowspan="1" colspan="1">15.5 (7.7)</td><td align="center" rowspan="1" colspan="1">21.7 (7.8)</td><td align="center" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline CDAI<xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Active</td><td align="center" rowspan="1" colspan="1">22(41.5)</td><td align="center" rowspan="1" colspan="1">21(38.2)</td><td align="center" rowspan="2" colspan="1">0.84</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Remission</td><td align="center" rowspan="1" colspan="1">31(58.5)</td><td align="center" rowspan="1" colspan="1">34(61.8)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>*</label><p> CDAI: Clinical disease activity index</p></fn></table-wrap-foot></table-wrap><p>In the present study, we investigated the effects of vitamin D<sub>3</sub> treatment on reduction TNF-&#x003b1; (one of the most important pro-inflammatory cytokine in IBD) levels and clinical activity disease index (CADI) in IBD patients. Oral intake of 50000 IU vitamin D3 once weekly for 12 weeks, significantly increased serum 25OHD levels from 15.54 to 67.89 (p= 0.00). Also, it reduced the TNF-&#x003b1; level from 33.3% to 26.64% but this reduction was not statistically significant (P=0.07). </p><p>Few clinical trials have been undertaken regarding the effect of vitamin D administration in IBD course and to our knowledge; this is one of the first clinical trials to estimate the effect of vitamin D3 treatment on IBD disease course with regarding to reduction of TNF-&#x003b1; level and CDAI. </p><p>In a pilot study on a limited number (n=18) Crohn's patients by Yang et al. vitamin D oral supplementation significantly increased serum 25-OHD levels and reduced the unadjusted mean CDAI (Crohn's disease activity index) scores. In this study markers of inflammation associated with disease such as CRP, ESR, TNF-&#x003b1;, IL-17, IL-10 and vascular endothelial growth factor was assessed before and after vitamin D<sub>3</sub> treatment but all of them didn&#x02019;t found to be affected by the vitamin D<sub>3</sub> supplementation (<xref rid="B24" ref-type="bibr">24</xref>). A large part of these results were similar to our results.</p><p>A meta-analysis study by Nicholson et al. in 2012 has reported that only four clinical trials (two of them examined human participants and the other two included experimental animals) have evaluated the effect vitamin D supplementation in inflammatory bowel disease (<xref rid="B25" ref-type="bibr">25</xref>). All of them demonstrate some benefits to use the vitamin D supplements but only two of these studies (animal&#x02019;s studies) had statistically significant results (26,27). Of course the results from animal studies are limited in their application to the human species. </p><p>The clinical trial by Jorgensen et al. reported a non-significant reduction of relapse rate for Crohn's disease compared to placebo (29% vs. 13%, P=0.06) (<xref rid="B28" ref-type="bibr">28</xref>). Also, another human clinical trial by Miheller et al. demonstrated the effects of one form of vitamin D has more effects in maintaining disease remission compared to the other form at the end of 6 weeks of the trial but not at the end of 12 months (<xref rid="B29" ref-type="bibr">29</xref>). </p><p>However, two retrospective cohort studies in inflammatory bowel disease found statistically significant results. In the first study, had examined vitamin D status influences durability of anti-tumor necrosis factor (TNF)-&#x003b1; therapy in patients with IBD. The findings showed patients with insufficient vitamin D because of the lack of response to treatment stopped anti-TNF-&#x003b1; therapy&#x000a0;earlier than sufficient subject (<xref rid="B30" ref-type="bibr">30</xref>).</p><p>Moreover, in another retrospective cohort study Ultisky et al. showed that vitamin D deficiency was associated with higher disease activity (<xref rid="B31" ref-type="bibr">31</xref>). However, there are some limitations in retrospective cohort studies. As the information was not specifically gathered for research purpose thus these studies may remind bias. </p><p>Current study also has some limitation such as the short-term period of treatment. Extending the treatment duration may help more comprehensive evaluation of the effects of vitamin D. The other limitation of our study is the lack of use of a placebo, given that the number of patients who were excluded from the control group more than the number of missing vitamin D group patients. This study as the first study about the association of vitamin D deficiency and inflammatory bowel disease in Iran has some strength points including relatively large sample size and the recruitment inclusion criterion of vitamin D deficiency or insufficiency. </p><p>The present study showed oral supplementation vitamin D<sub>3</sub> significantly increased serum 25OHD levels and insignificantly reduced serum TNF-&#x003b1; level. However, more studies with larger samples would be beneficial to assess vitamin D<sub>3</sub> supplementation efficient effect in IBD.</p></sec></body><back><ack><title>Acknowledgment</title><p>The present study has been extracted from a student thesis for the degree specialist (post specialist) in field of gastroenterology. The authors are thankful to Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences for their kindly support of the project.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumgart</surname><given-names>DC</given-names></name><name><surname>Carding</surname><given-names>SR</given-names></name></person-group><article-title>Inflammatory bowel disease: cause and immuno biology</article-title><source> Lancet</source><year>2007</year><volume>369</volume><fpage>1627</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">17499605</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Munoz</surname><given-names>F</given-names></name><name><surname>Dominguez-Lopez</surname><given-names>A</given-names></name><name><surname>Yamamoto-Furusho</surname><given-names>JK</given-names></name></person-group><article-title>Role of cytokines in inflammatory bowel disease</article-title><source> World J Gastroenterol</source><year>2008</year><volume>14</volume><fpage>4280</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">18666314</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halme</surname><given-names>L</given-names></name><name><surname>Paavola-Sakki</surname><given-names>P</given-names></name><name><surname>Turunen</surname><given-names>U</given-names></name><name><surname>Lappalainen</surname><given-names>M</given-names></name><name><surname>Farkkila</surname><given-names>M</given-names></name><name><surname>Kontula</surname><given-names>K</given-names></name></person-group><article-title>Family and twin studies in inflammatory bowel disease</article-title><source> World J Gastroenterol</source><year>2006</year><volume>12</volume><fpage>3668</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">16773682</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ananthakrishnan</surname><given-names>AN</given-names></name></person-group><article-title>Environmental&#x000a0;risk factors&#x000a0;for&#x000a0;inflammatory bowel disease</article-title><source> Gastroenterol Hepatol&#x000a0;</source><year>2013</year><volume>9</volume><fpage>367</fpage><lpage>74</lpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farnood</surname><given-names>A</given-names></name><name><surname>Naderi</surname><given-names>N</given-names></name><name><surname>Moghaddam</surname><given-names>SJ</given-names></name><name><surname>Noorinayer</surname><given-names>B</given-names></name><name><surname>Firouzi</surname><given-names>F</given-names></name><name><surname>Aghazadeh</surname><given-names>R</given-names></name><etal/></person-group><article-title>The frequency of C3435T MDR1 gene polymorphism in Iranian patients with ulcerative colitis</article-title><source> Int J Colorectal Dis</source><year>2007</year><volume>22</volume><fpage>999</fpage><lpage>1003</lpage><pub-id pub-id-type="pmid">17242936</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>MT</given-names></name><name><surname>Weaver</surname><given-names>CT</given-names></name></person-group><article-title>Linking vitamin D deficiency to inflammatory bowel disease</article-title><source> Inflamm Bowel Dis</source><year>2013</year><volume>19</volume><fpage>2245</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">23591600</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hypponen</surname><given-names>E</given-names></name><name><surname>Laara</surname><given-names>E</given-names></name><name><surname>Reunanen</surname><given-names>A</given-names></name><name><surname>Jarvelin</surname><given-names>MR</given-names></name><name><surname>Virtanen</surname><given-names>SM</given-names></name></person-group><article-title>Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study</article-title><source> Lancet</source><year>2001</year><volume>358</volume><fpage>1500</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">11705562</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackenzie</surname><given-names>IS</given-names></name><name><surname>Morant</surname><given-names>SV</given-names></name><name><surname>Bloomfield</surname><given-names>GA</given-names></name><name><surname>Mac</surname><given-names>Donald TM</given-names></name><name><surname>O'Riordan</surname><given-names>J</given-names></name></person-group><article-title>Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database</article-title><source> J Neurol Neurosurg Psychiatry&#x000a0;</source><year>2014</year><volume>85</volume><fpage>76</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">24052635</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Provvedini</surname><given-names>DM</given-names></name><name><surname>Tsoukas</surname><given-names>CD</given-names></name><name><surname>Deftos</surname><given-names>LJ</given-names></name><name><surname>Manolagas</surname><given-names>SC</given-names></name></person-group><article-title>1,25-Dihydroxyvitamin D3 receptors in human leukocytes</article-title><source> Science</source><year>1983</year><volume>221</volume><fpage>1181</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">6310748</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagpal</surname><given-names>S</given-names></name><name><surname>Na</surname><given-names>S</given-names></name><name><surname>Rathnachalam</surname><given-names>R</given-names></name></person-group><article-title>Noncalcemic actions of vitamin D receptor ligands</article-title><source> Endocr Rev</source><year>2005</year><volume>26</volume><fpage>662</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">15798098</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peelen</surname><given-names>E</given-names></name><name><surname>Knippenberg</surname><given-names>S</given-names></name><name><surname>Muris</surname><given-names>AH</given-names></name><name><surname>Thewissen</surname><given-names>M</given-names></name><name><surname>Smolders</surname><given-names>J</given-names></name><name><surname>Tervaert</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Effects of vitamin D on the peripheral adaptive immune system: a review</article-title><source> Autoimmun Rev</source><year>2011</year><volume>10</volume><fpage>733</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">21621002</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>JD</given-names></name><name><surname>Mullighan</surname><given-names>C</given-names></name><name><surname>Welsh</surname><given-names>KI</given-names></name><name><surname>Jewell</surname><given-names>DP</given-names></name></person-group><article-title>Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility</article-title><source> Gut</source><year>2000</year><volume>47</volume><fpage>211</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">10896912</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dresner-Pollak</surname><given-names>R</given-names></name><name><surname>Ackerman</surname><given-names>Z</given-names></name><name><surname>Eliakim</surname><given-names>R</given-names></name><name><surname>Karban</surname><given-names>A</given-names></name><name><surname>Chowers</surname><given-names>Y</given-names></name><name><surname>Fidder</surname><given-names>HH</given-names></name></person-group><article-title>The BsmI vitamin D receptor gene polymorphism is associated with ulcerative colitis in Jewish Ashkenazi patients</article-title><source> Genet Test</source><year>2004</year><volume>8</volume><fpage>417</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">15684874</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><etal/></person-group><article-title>Protective&#x000a0;role&#x000a0;of 1,25(OH)2 vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice</article-title><source> BMC Gastroenterol</source><year>2012</year><volume>30</volume><fpage>12</fpage><lpage>57</lpage></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantorna</surname><given-names>MT</given-names></name></person-group><article-title>Mechanisms underlying the effect of vitamin D on the immune system</article-title><source> Proc Nutr Soc</source><year>2010</year><volume>69</volume><fpage>286</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">20515520</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardizzone</surname><given-names>S</given-names></name><name><surname>Cassinotti</surname><given-names>A</given-names></name><name><surname>Bevilacqua</surname><given-names>M</given-names></name><name><surname>Clerici</surname><given-names>M</given-names></name><name><surname>Porro</surname><given-names>GB</given-names></name></person-group><article-title>Vitamin D and inflammatory bowel disease</article-title><source> Vitam Horm</source><year>2011</year><volume>86</volume><fpage>367</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">21419280</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Feldman</surname><given-names>M</given-names></name><name><surname>Friedman</surname><given-names>LS</given-names></name><name><surname>Brandt</surname><given-names>LJ</given-names></name></person-group><source>Sleisenger and Fordtran's Gastrointestinal and Liver Disease</source><year>2010</year><edition>9th ed</edition><publisher-loc>Philadelphia</publisher-loc><publisher-name>Saunders</publisher-name></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Best</surname><given-names>WR</given-names></name><name><surname>Becktel</surname><given-names>JM</given-names></name><name><surname>Singleton</surname><given-names>JW</given-names></name><name><surname>Kern</surname><given-names>F Jr</given-names></name></person-group><article-title>Development of a Crohn's disease activity index National Cooperative Crohn's Disease Study</article-title><source> Gastroenterology</source><year>1976</year><volume>70</volume><fpage>439</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">1248701</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponsonby</surname><given-names>AL</given-names></name><name><surname>Mc</surname><given-names>Michael A</given-names></name><name><surname>van</surname><given-names>der Mei I</given-names></name></person-group><article-title>Ultraviolet radiation and autoimmune disease: insights from epidemiological research</article-title><source> Toxicology</source><year>2002</year><volume>181-182</volume><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">12505287</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantorna</surname><given-names>MT</given-names></name></person-group><article-title>Vitamin D&#x000a0;and&#x000a0;multiple sclerosis: an&#x000a0;update</article-title><source> Nutr Rev&#x000a0;</source><year>2008</year><volume>66</volume><fpage>S135</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">18844840</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>B</given-names></name></person-group><article-title>Bone loss in patients with the ileostomy and ileal pouch for inflammatory bowel disease</article-title><source> Gastroenterol Rep</source><year>2013</year><volume>1</volume><fpage>159</fpage><lpage>65</lpage></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantorna</surname><given-names>MT</given-names></name><name><surname>Munsick</surname><given-names>C</given-names></name><name><surname>Bemiss</surname><given-names>C</given-names></name><name><surname>Mahon</surname><given-names>BD</given-names></name></person-group><article-title>1,25-Dihydroxy cholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease</article-title><source> J Nutr</source><year>2000</year><volume>130</volume><fpage>2648</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">11053501</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniel</surname><given-names>C</given-names></name><name><surname>Radeke</surname><given-names>HH</given-names></name><name><surname>Sartory</surname><given-names>NA</given-names></name><name><surname>Zahn</surname><given-names>N</given-names></name><name><surname>Zuegel</surname><given-names>U</given-names></name><name><surname>Steinmeyer</surname><given-names>A</given-names></name><etal/></person-group><article-title>The new low calcemic vitamin D analog 22-ene-25-oxa-vitamin D prominently ameliorates T helper cell type 1-mediated colitis in mice</article-title><source> J Pharmacol Exp Ther</source><year>2006</year><volume>319</volume><fpage>622</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">16914561</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Weaver</surname><given-names>V</given-names></name><name><surname>Smith</surname><given-names>JP</given-names></name><name><surname>Bingaman</surname><given-names>S</given-names></name><name><surname>Hartman</surname><given-names>TJ</given-names></name><name><surname>Cantorna</surname><given-names>MT</given-names></name></person-group><article-title>Therapeutic effects of vitamin D supplementation in a pilot study of Crohn's patients</article-title><source> Clin Transl Gastroenterol</source><year>2013</year><volume>4</volume><lpage>e33</lpage></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>I</given-names></name><name><surname>Dalzell</surname><given-names>AM</given-names></name><name><surname>El-Matary</surname><given-names>W</given-names></name></person-group><article-title>Vitamin D as a therapy for colitis: a systematic review</article-title><source> J Crohn&#x02019;s Colitis</source><year>2012</year><volume>6</volume><fpage>405</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">22398085</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantorna</surname><given-names>MT</given-names></name><name><surname>Munsick</surname><given-names>C</given-names></name><name><surname>Bemiss</surname><given-names>C</given-names></name><name><surname>Mahon</surname><given-names>BD</given-names></name></person-group><article-title>1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease</article-title><source> J Nutr</source><year>2000</year><volume>130</volume><fpage>2648</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">11053501</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniel</surname><given-names>C</given-names></name><name><surname>Schlauch</surname><given-names>T</given-names></name><name><surname>Z&#x000fc;gel</surname><given-names>U</given-names></name><name><surname>Steinmeyer</surname><given-names>A</given-names></name><name><surname>Radeke</surname><given-names>HH</given-names></name><name><surname>Steinhilber</surname><given-names>D</given-names></name><etal/></person-group><article-title>22-ene-25-oxa-vitamin D: A new vitamin D analogue with profound immunosuppressive capacities</article-title><source> Eur J Clin Invest</source><year>2005</year><volume>35</volume><fpage>343</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">15860047</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname><given-names>SP</given-names></name><name><surname>Agnholt</surname><given-names>J</given-names></name><name><surname>Glerup</surname><given-names>H</given-names></name><name><surname>Lyhne</surname><given-names>S</given-names></name><name><surname>Villadsen</surname><given-names>GE</given-names></name><name><surname>Hvas</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Clinical trial: vitamin D3 treatment in Crohn's disease- a randomized double-blind placebo-controlled study</article-title><source> Aliment Pharmacol Ther</source><year>2010</year><volume>32</volume><fpage>377</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">20491740</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miheller</surname><given-names>P</given-names></name><name><surname>Muzes</surname><given-names>G</given-names></name><name><surname>Hritz</surname><given-names>I</given-names></name><name><surname>Lakatos</surname><given-names>G</given-names></name><name><surname>Pregun</surname><given-names>I</given-names></name><name><surname>LakatosPL</surname><given-names/></name><etal/></person-group><article-title>Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients</article-title><source> Inflamm Bowel Dis</source><year>2009</year><volume>15</volume><fpage>1656</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">19408329</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zator</surname><given-names>ZA</given-names></name><name><surname>Cantu</surname><given-names>SM</given-names></name><name><surname>Konijeti</surname><given-names>GG</given-names></name><name><surname>Nguyen</surname><given-names>DD</given-names></name><name><surname>Sauk</surname><given-names>J</given-names></name><name><surname>Yajnik</surname><given-names>V</given-names></name><etal/></person-group><article-title>Pretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor-&#x003b1; therapy in inflammatory bowel diseases</article-title><source> JPEN J Parenter Enteral Nutr</source><year>2014</year><volume>38</volume><fpage>385</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">24088707</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulitsky</surname><given-names>A</given-names></name><name><surname>Ananthakrishnan</surname><given-names>AN</given-names></name><name><surname>Naik</surname><given-names>A</given-names></name><name><surname>Skaros</surname><given-names>S</given-names></name><name><surname>Zadvornova</surname><given-names>Y</given-names></name><name><surname>Binion</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life</article-title><source> JPEN J Parenter Enteral Nutr</source><year>2011</year><volume>35</volume><fpage>308</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">21527593</pub-id></element-citation></ref></ref-list></back></article>